Trial Profile
Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2014
Price :
$35
*
At a glance
- Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms STEALTH C-3
- Sponsors Romark Laboratories
- 30 May 2012 Actual end date Apr 2010 added as reported by ClinicalTrials.gov.
- 30 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 May 2010 Results presented orally at the Late-Breaking forum of the American Gastroenterological Association Institute during Digestive Disease Week (DDW), as reported by Romark Laboratories.